Fig. 2.

Five-year relative survival and 95% confidence intervals of adults (ages ≥ 20 years at acute myeloid leukemia (AML) diagnosis) with diagnostically confirmed first primary AML who were diagnosed 2001–2018 (followed through 2019) and reported to have received initial chemotherapy for total AML according to A) age at diagnosis, B) sex, and C) calendar year period of diagnosis identified in 17 cancer registry areas of the Surveillance, Epidemiology, and End Results Program.